December 12, 2018
Daiichi Sankyo has forged a strategic oncology development collaboration with Nashville, Tennessee-based Sarah Cannon Research Institute, which will encompass the Japanese company’s antibody drug conjugate (ADC) franchise, the two companies said on December 10. Sarah Cannon, which has CRO unit...read more